191 related articles for article (PubMed ID: 34037837)
1. The status of WIF1 methylation in cell-free DNA is associated with the insusceptibility for gefitinib in the treatment of lung cancer.
Shen Z; Chen C; Sun J; Huang J; Liu S
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2239-2248. PubMed ID: 34037837
[TBL] [Abstract][Full Text] [Related]
2. miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1.
Zhang H; Hu B; Wang Z; Zhang F; Wei H; Li L
Cancer Chemother Pharmacol; 2017 Nov; 80(5):973-984. PubMed ID: 28956120
[TBL] [Abstract][Full Text] [Related]
3. Wif1 hypermethylation as unfavorable prognosis of non-small cell lung cancers with EGFR mutation.
Lee SM; Park JY; Kim DS
Mol Cells; 2013 Jul; 36(1):69-73. PubMed ID: 23686431
[TBL] [Abstract][Full Text] [Related]
4. Plasma cfDNA as a potential treatment monitoring and prognostic index in patients withnon-small cell lung cancer.
Chen N; Li G; Li H; Xiang X; Guo G; Ma Q; Zhang Y
Cell Mol Biol (Noisy-le-grand); 2020 Jul; 66(5):208-213. PubMed ID: 33040838
[TBL] [Abstract][Full Text] [Related]
5. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
Ge P; Cao L; Chen X; Jing R; Yue W
BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
[TBL] [Abstract][Full Text] [Related]
6. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
7. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer.
Balgkouranidou I; Chimonidou M; Milaki G; Tsarouxa EG; Kakolyris S; Welch DR; Georgoulias V; Lianidou ES
Br J Cancer; 2014 Apr; 110(8):2054-62. PubMed ID: 24642624
[TBL] [Abstract][Full Text] [Related]
9. KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer.
Mastoraki S; Balgkouranidou I; Tsaroucha E; Klinakis A; Georgoulias V; Lianidou E
Mol Oncol; 2021 Sep; 15(9):2412-2422. PubMed ID: 33159839
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic role of Wnt pathway gene promoter methylation in non small cell lung cancer.
Liu S; Chen X; Chen R; Wang J; Zhu G; Jiang J; Wang H; Duan S; Huang J
Oncotarget; 2017 May; 8(22):36354-36367. PubMed ID: 28422739
[TBL] [Abstract][Full Text] [Related]
11. Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.
Li XY; Wu JZ; Cao HX; Ma R; Wu JQ; Zhong YJ; Feng JF
Oncol Rep; 2013 May; 29(5):1975-82. PubMed ID: 23440266
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA‑506‑3p reverses gefitinib resistance in non‑small cell lung cancer by targeting Yes‑associated protein 1.
Zhu J; Tao L; Jin L
Mol Med Rep; 2019 Feb; 19(2):1331-1339. PubMed ID: 30535506
[TBL] [Abstract][Full Text] [Related]
13. Study of the methylation patterns of the EGFR gene promoter in non-small cell lung cancer.
Pan ZY; Jiang ZS; Ouyang HQ
Genet Mol Res; 2015 Aug; 14(3):9813-20. PubMed ID: 26345914
[TBL] [Abstract][Full Text] [Related]
14. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
[TBL] [Abstract][Full Text] [Related]
15. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
[TBL] [Abstract][Full Text] [Related]
16. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.
Cappuzzo F; Jänne PA; Skokan M; Finocchiaro G; Rossi E; Ligorio C; Zucali PA; Terracciano L; Toschi L; Roncalli M; Destro A; Incarbone M; Alloisio M; Santoro A; Varella-Garcia M
Ann Oncol; 2009 Feb; 20(2):298-304. PubMed ID: 18836087
[TBL] [Abstract][Full Text] [Related]
17. Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines.
Li ZX; Qu LY; Wen H; Zhong HS; Xu K; Qiu XS; Wang EH
Int J Clin Exp Pathol; 2014; 7(10):7304-11. PubMed ID: 25400829
[TBL] [Abstract][Full Text] [Related]
18. Wnt inhibitory factor 1 (WIF1) methylation and its association with clinical prognosis in patients with chondrosarcoma.
Liu P; Shen JK; Hornicek FJ; Liu F; Duan Z
Sci Rep; 2017 May; 7(1):1580. PubMed ID: 28484252
[TBL] [Abstract][Full Text] [Related]
19. Real-life Effectiveness of Afatinib
Svaton M; Bratova M; Fischer O; Krejci J; Koubkova L; Cernovska M; Hrnciarik M; Zemanova M; Coupkova H; Porzer B; Dolezal D; Tuzova T; Hurdalkova K; Barinova M; Skrickova J
Anticancer Res; 2021 Apr; 41(4):2059-2065. PubMed ID: 33813414
[TBL] [Abstract][Full Text] [Related]
20. Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell Lung Cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5p.
Ma G; Zhu J; Liu F; Yang Y
DNA Cell Biol; 2019 Feb; 38(2):176-183. PubMed ID: 30601026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
